CDX2 Antibody Clone: GR023 Concentrate
- Known as:
- CDX2 Antibody Clone: GR023 Concentrate
- Catalog number:
- 61-0186-2
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Genemed
- Gene target:
- CDX2 Antibody Clone: GR023 Concentrate
Related genes to: CDX2 Antibody Clone: GR023 Concentrate
- Gene:
- CDX2 NIH gene
- Name:
- caudal type homeobox 2
- Previous symbol:
- CDX3
- Synonyms:
- -
- Chromosome:
- 13q12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1994-09-07
- Date modifiied:
- 2015-08-24
Related products to: CDX2 Antibody Clone: GR023 Concentrate
Related articles to: CDX2 Antibody Clone: GR023 Concentrate
- Colorectal cancer is the third most common cancer worldwide, and as such is a significant global health concern. Distant metastases of colorectal cancer to the lung, liver, and bone are well documented, while gastrointestinal tract (GIT) metastases are very rare. Herein, we report a case of gastric metastasis from sigmoid colon cancer. A 78-year-old male was diagnosed with both gastric and colorectal cancer, which occurred synchronously. The presence of two primary cancers was diagnosed, and radical subtotal gastrectomy and anterior resection were performed simultaneously. The postoperative pathology report showed a moderately differentiated adenocarcinoma in the sigmoid colon and stomach. Immunohistochemical (IHC) analysis revealed that the resected gastric specimens showed tumor cells that were positive for both cytokeratin 20 (CK20) and caudal-type homeobox gene 2 (CDX2) and negative for CK7. This confirmed that the gastric lesion was a metastasis from colorectal cancer. Clinicians should be aware of the potential presence of metastatic gastric cancer, whether synchronous or metachronous, in other solid organ malignancies. - Source: PubMed
Publication date: 2026/04/12
Oh Seung JongOh Seul-GiChoi Sun Keun - Gastrointestinal malignancies (GIs) - especially the colon adenocarcinoma (CAD) - represent the third leading cause of cancer-related morbidity and mortality, respectively. The development and progression of CAD is a multistep procedure in which a variety of deregulated molecules are implicated. Among them, the special AT-rich sequence-binding protein 2 (SATB2, gene locus: 2q33.1) seems to be a reliable marker for differential diagnosis and prognosis in patients suffering from GIs. - Source: PubMed
Davris DimitriosFalidas EvangelosAdamopoulou MariaTsiambas EvangelosMetaxas Ioanna EPoultsidi AntigoniTzovaras GeorgeZacharoulis Dimitrios - Nab-paclitaxel, a nanoparticle formulation of paclitaxel, is commonly used to treat solid tumors but is associated with rare adverse effects, including cystoid macular oedema (CMO). This case highlights the CMO in a patient undergoing nab-paclitaxel treatment for metastatic pancreatic cancer. - Source: PubMed
Shivarthi TejasHaridas SujithraPavithran Keechilat - Malignant mesothelioma is a rare malignant neoplasm of mesothelial origin, with primary involvement of the greater omentum being exceptionally uncommon. Nonspecific clinical manifestations often lead to misdiagnosis, and cases without asbestos exposure further increase diagnostic complexity. - Source: PubMed
Publication date: 2026/03/26
Gan XuemeiTuo YinglanHuang LanYang QinLiu Hong - I read with great interest the recent article by Zelga et al. regarding the clinicopathological distinctions between ventral and dorsal IPMNs. While we commend the authors for elucidating the embryological basis of these differences, specifically the role of CDX2, I propose that anatomical proximity to the duodenum and consequent reflux may act as environmental cofactors driving intestinal differentiation. Furthermore, regarding the higher malignancy rate in dorsal IPMNs with mild main pancreatic duct dilation (5-9 mm), I suggest this reflects the physiological tapering of the duct in the tail. A 5-mm dilation in the distal pancreas represents a severe relative obstruction compared to the head. We advocate for future guidelines to incorporate relative ductal caliber to optimize surveillance strategies. - Source: PubMed
Publication date: 2026/04/09
Takahashi Koji